Cotellic for Advanced Melanoma Launched
Genentech announced the launch of Cotellic (cobimetinib) for the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf (vemurafenib), available immediately at Biologics. Cotellic was approved by the Food and Drug Administration (FDA) on November 10, 2015.
Physicians may submit Cotellic prescriptions to Biologics via phone [(800) 850-4306, option 2], fax [(800) 823-4506] or eScribe.
Cotellic is available as 20mg dosage strength and is supplied in bottles of 63 tablets.